<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4BCC4C8C-5B59-42E4-9E98-F60F7A4E0C2C"><gtr:id>4BCC4C8C-5B59-42E4-9E98-F60F7A4E0C2C</gtr:id><gtr:name>Birmingham Women's and Children's NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A5E72F91-30E2-45E6-8D19-EDC197FF970A"><gtr:id>A5E72F91-30E2-45E6-8D19-EDC197FF970A</gtr:id><gtr:name>Monash University</gtr:name><gtr:address><gtr:line1>Monash University</gtr:line1><gtr:line2>Level 1, Chancellery Building D</gtr:line2><gtr:line3>26 Sports Walk, Wellington Road</gtr:line3><gtr:postCode>3800</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC"><gtr:id>8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC</gtr:id><gtr:name>Lancaster University</gtr:name><gtr:address><gtr:line1>,</gtr:line1><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4BCC4C8C-5B59-42E4-9E98-F60F7A4E0C2C"><gtr:id>4BCC4C8C-5B59-42E4-9E98-F60F7A4E0C2C</gtr:id><gtr:name>Birmingham Women's and Children's NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A5E72F91-30E2-45E6-8D19-EDC197FF970A"><gtr:id>A5E72F91-30E2-45E6-8D19-EDC197FF970A</gtr:id><gtr:name>Monash University</gtr:name><gtr:address><gtr:line1>Monash University</gtr:line1><gtr:line2>Level 1, Chancellery Building D</gtr:line2><gtr:line3>26 Sports Walk, Wellington Road</gtr:line3><gtr:postCode>3800</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC"><gtr:id>8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC</gtr:id><gtr:name>Lancaster University</gtr:name><gtr:address><gtr:line1>,</gtr:line1><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A415FBFD-F657-4BE1-B8B7-33C8B25DA5E9"><gtr:id>A415FBFD-F657-4BE1-B8B7-33C8B25DA5E9</gtr:id><gtr:firstName>Matthew</gtr:firstName><gtr:otherNames>Robert</gtr:otherNames><gtr:surname>Sydes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A0A1A9F6-1AA6-4F4E-8CB7-B1274A99660F"><gtr:id>A0A1A9F6-1AA6-4F4E-8CB7-B1274A99660F</gtr:id><gtr:firstName>Louise</gtr:firstName><gtr:otherNames>C</gtr:otherNames><gtr:surname>BROWN</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DF6C47B2-3280-4689-97A4-102C07D23553"><gtr:id>DF6C47B2-3280-4689-97A4-102C07D23553</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Copas</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/19A5EF50-2396-4D36-AD21-CAF54F14DFBF"><gtr:id>19A5EF50-2396-4D36-AD21-CAF54F14DFBF</gtr:id><gtr:firstName>Patrick</gtr:firstName><gtr:otherNames>Peter</gtr:otherNames><gtr:surname>Phillips</gtr:surname><gtr:orcidId>0000-0002-6336-7024</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C2ADAD1C-4A0B-4FFE-BEC7-6C6CAF45BB60"><gtr:id>C2ADAD1C-4A0B-4FFE-BEC7-6C6CAF45BB60</gtr:id><gtr:firstName>Max</gtr:firstName><gtr:surname>Parmar</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12023%2F29"><gtr:id>656DC089-644D-4BF4-945B-4103452367AA</gtr:id><gtr:title>Design of Trials, Meta-analyses and observational studies</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12023/29</gtr:grantReference><gtr:abstractText>The CTU-pioneered multi-arm, multi-stage trial design (MAMS), allows efficient evaluation of multiple treatments and the flexibility to drop inactive treatment arms and incorporate new ones. This has been demonstrated in our ongoing STAMPEDE trial in prostate cancer, which added a new arms since 2012. We also began to design a new CTU MAMS trial of novel tuberculosis regimens, and worked with other groups to develop potential MAMS trials in osteosarcoma, hepatobiliary cancer, melanoma, dermatology and multiple sclerosis. We also ran a workshop on MAMS methodology, leading to further requests for help to develop MAMS trials in other diseases. There are many new agents demanding assessment, and a need to evaluate biomarkers that effectively identify more responsive patient subgroups. Our FOCUS4 trial (funded 2012) in colorectal cancer represents a new approach to trial design, linking the evaluation of five novel treatments to the assessment of potentially predictive biomarkers in a multi-staged framework. It offers the flexibility to refine and introduce new biomarkers and/or new therapies, and introduces a new paradigm in oncology. Already, others are considering similar trials in pancreatic and upper gastrointestinal cancer.</gtr:abstractText><gtr:technicalSummary>There is an urgent need for new methods for many clinical studies. In particular, we need more rapid, efficient and better evaluation of therapies. This is partly because of the increase in numbers of new therapeutic approaches demanding evaluation, and the staggering failure rate to show that the ?new? is better than the ?old?. Also, phase III trials often require large numbers of patients, take a long time, and cost many millions of pounds. One of the principal ways to improve this situation is through better trial designs.

Motivated by, and directly relevant to, the real challenges of clinical research, and very commonly those faced directly in studies conducted by the MRC Clinical Trial Unit (CTU) we focus on multi-arm, multi-stage platform trials; designing phase II (and III trials) based on an enhanced decision process at the end of phase II; improving the design of stratified medicine trials and biomarker validation studies; designing trials in uncommon diseases and cluster randomised and stepped wedge trials. Also, we want to establish a flexible framework for time-to-event designs, be better able to account for non-proportional hazards, missing data, repeated measures and recurrent events in trial design and explore the possibility of re-randomising participants into trials. In addition, we are investigating sample size estimation for developing and validating prognostic models.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>406000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Re-randomisation of patients to a clinical trial</gtr:description><gtr:id>EE4FB42D-6080-46EB-ADE7-C7D904451CDE</gtr:id><gtr:impact>Several invited seminars (Leeds, Leicester, LSHTM), conference papers, one published paper.</gtr:impact><gtr:outcomeId>56d6b9eedfabb7.17819060-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input to original design and resulting paper; currently working on follow up projects to demonstrate strengths and weaknesses and to understand practicalities of the design.</gtr:partnerContribution><gtr:piContribution>Intellectual input to original design and resulting paper; currently working on follow up projects to demonstrate strengths and weaknesses and to understand practicalities of the design</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lancaster University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>B1- Big Idea- Adaptive Design Outreach officer</gtr:description><gtr:id>38A2E754-8180-4A29-ADF4-B58D0629B4C5</gtr:id><gtr:impact>ongoing</gtr:impact><gtr:outcomeId>545a28e1a83d10.57759263-1</gtr:outcomeId><gtr:partnerContribution>This proposal is for an &amp;quot;Adaptive Design Outreach Officer&amp;quot; who would be associated with the Adaptive Designs Working Group (ADWG). The key aim would be to raise awareness and use of adaptive designs across a broad range of diseases and across the development and assessment spectrum. Adaptive methods in this context are defined in its broadest sense end will include Bayesian adaptive dose-finding and group-sequential methods, multi-arm trials, lack-of-benefit stopping rules and sample size reassessment methods. The main activity of the outreach officer would be to proactively engage with applied health researchers to discuss the merits and relative drawbacks of the currently available adaptive designs. In particular, the outreach officer would: 
1. Develop training material on current adaptive designs 
2. Visit each of the UKCRC registered Clinical Trials Units1 to present about the potential of adaptive designs 
3. Facilitate the uptake and implementation of adaptive designs 
4. Support the writing of tutorial papers on adaptive designs</gtr:partnerContribution><gtr:piContribution>Network funding provided for this post</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Network of Hubs for Trials Methodology Research (HTMR)</gtr:department><gtr:description>Adaptive Designs Working Group</gtr:description><gtr:id>35CD6BDC-05BC-4C26-9B1B-A02039C68822</gtr:id><gtr:impact>Adaptive designs meet regularly and host an annual meeting on their research.

There is an adaptive design outreach officer - paid for by the Network- who is undertaking regular visits to CTUs and is working on new research methodologies. To date (2016 Feb) 7 CTUs have been visited, and they have collaborated with one group on developing a trial application</gtr:impact><gtr:outcomeId>56d6b79c6b25b5.03625074-1</gtr:outcomeId><gtr:partnerContribution>Scope: The Adaptive Designs Working Group collaborates to increase uptake of methods, to improve knowledge and to link with key stakeholders such as regulators and industry in this important area for improving the speed and efficiency of trials. Future objectives: The Network plays a vital role in increasing the implementation of adaptive design methodology, with the main barriers to implementation already identified as a lack of software and a lack of expertise. The future plans for this group include continued annual meetings, strengthening the engagement with industry and the development of collaborative inter-Hub visits to develop novel adaptive designs. The group is focusing its efforts on preparing tutorial papers for applied journals and mainstream medical journals; presentations and lectures to increase uptake of methods among stakeholders; and the development of computer software to help researchers to undertake trials with adaptive designs.</gtr:partnerContribution><gtr:piContribution>The HTMR Network supported the Adaptive Designs Working Group (WG) to regularly meet and exchange ideas. This involves members of the methodology community and Hub members.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Stepped wedge trial design</gtr:description><gtr:id>B1720DF8-23FF-4274-BB42-820D6D49F221</gtr:id><gtr:impact>Special issue of Trials (6 articles), workshop to present the findings. Further collaboration with other parts of UCL as well as with LSHTM. Work is already being cited.</gtr:impact><gtr:outcomeId>56d84633c3a129.37643224-1</gtr:outcomeId><gtr:partnerContribution>Intellectual contributions</gtr:partnerContribution><gtr:piContribution>Intellectual contribution to all activities, lead authorship on one of 6 publications</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amgen Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Making decisions at the end of a Phase 2 clinical trial</gtr:description><gtr:id>CDC80E63-4973-4F5F-B67C-E2D73A792419</gtr:id><gtr:impact>2 research papers published and a further paper has been submitted; has had implications for how trial design decisions are made within Amgen</gtr:impact><gtr:outcomeId>56d6bc1998d790.96750494-1</gtr:outcomeId><gtr:partnerContribution>Methodological development and simulation work as part of a PhD research project</gtr:partnerContribution><gtr:piContribution>Methodological development of an approach to the decision as to whether to proceed to a phase three trial at the end of phase two that synthesizes the available data. An exploration as to how this can also be used to design trials at phase two and three.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Network of Hubs for Trials Methodology Research (HTMR)</gtr:department><gtr:description>Stratified Medicine WG</gtr:description><gtr:id>AE54AD3B-BB93-487F-872C-10E92291DA30</gtr:id><gtr:impact>ongoing collaborations.</gtr:impact><gtr:outcomeId>545a1aa4ed8e65.77288952-1</gtr:outcomeId><gtr:partnerContribution>Scope- Stratified Medicine is about tailoring treatments to specific patients, helping to ensure the highest chance of benefit and minimising the potential for harm or unnecessary treatment
 
The Stratified Medicine Working Group collaborates to look at novel designs for biomarker-stratified trials, and to bring the stratified medicine approach into a wider range of disease areas, complementing work already done in the widely studied examples of cancer and heart disease.
 
Future Objectives- The Working Group is preparing a guidance paper to help people reading a stratified medicine research paper, and has started to explore means for delivering advice to applicants to the MRC Research Panel on Stratified Medicine. Members of the Working Group are also planning to develop prognostic models that help in the prediction of harms and benefits following the use of thrombolysis to treat stroke, drawing on individual participant data meta-analysis of clinical trials.</gtr:partnerContribution><gtr:piContribution>The HTMR Network supports the Stratified Medicine Working Group (WG) to regularly meet and exchange ideas. This involves members of the methodology community and Hub members.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Methodology Research Collaboration with industry</gtr:description><gtr:id>9C9D17E0-376F-445E-AA7B-B3F776BA8066</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56d6bdc221c2c3.85148695-1</gtr:outcomeId><gtr:partnerContribution>Commitment to developing research activity in to design, conduct or analysis methodology in areas of mutual interest. Detailed discussions ongoing</gtr:partnerContribution><gtr:piContribution>Commitment to developing research activity in to design, conduct or analysis methodology in areas of mutual interest. Detailed discussions ongoing</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Biostatistics Unit</gtr:department><gtr:description>Clinical trials in small populations: methodological challenges and solutions (N68)</gtr:description><gtr:id>31E51DF8-F795-4BF4-889D-9A3A2B4CD321</gtr:id><gtr:impact>A two-day meeting bringing together methodologists, applied statisticians, patient representatives and regulators to disseminate state-of-the-art methods and set priorities for methodological research in trials in small populations</gtr:impact><gtr:outcomeId>56d852b956d7b0.68442836-2</gtr:outcomeId><gtr:partnerContribution>Co-applicants and part of the organising committee for a national 2-day workshop</gtr:partnerContribution><gtr:piContribution>Co-applicants and part of the organising committee for a national 2-day workshop</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Sample size calculations for cluster randomised trials</gtr:description><gtr:id>6F1360C5-AFA7-4482-9E00-DCDEB44BB662</gtr:id><gtr:impact>Two research papers have been published and a presentation has been made at a conference. One further article is in development</gtr:impact><gtr:outcomeId>56d6bb97c0dd01.70370334-1</gtr:outcomeId><gtr:partnerContribution>Joint supervision of PhD student</gtr:partnerContribution><gtr:piContribution>Review of how sample size calculations are made and reported in cluster randomised trials, critical review of the published sample formulae with practical guidance. Further work will include development of guidance for calculating sample size for trials with an ordinal outcome</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Clustering and covariates in the design and analysis of RCTs</gtr:description><gtr:id>FA7D4112-4B58-4F29-8064-7F427537BA1D</gtr:id><gtr:impact>A number of publications have resulted from this collaboration, for example PMID: 23825027, 24749914, 24755011, 24456267. More are forthcoming.</gtr:impact><gtr:outcomeId>56d6ba8c5dd341.86562256-1</gtr:outcomeId><gtr:partnerContribution>Leadership of the project</gtr:partnerContribution><gtr:piContribution>Initiator of collaboration; provide expertise and intellectual input</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Biostatistics Unit</gtr:department><gtr:description>Collaborative research with MRC BSU</gtr:description><gtr:id>9227D3C0-71F3-4AD6-B5E8-ED368C4C79FC</gtr:id><gtr:impact>Several papers including PUBMED id: 19153970; 19452569; 21225900</gtr:impact><gtr:outcomeId>56d6bcde1670e9.24671734-1</gtr:outcomeId><gtr:partnerContribution>Joint collaborative research in design and analysis of clinical trials</gtr:partnerContribution><gtr:piContribution>Joint collaborative research in design and analysis of clinical trials</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre of Evidence Based Dermatology</gtr:department><gtr:description>MAMS design for erosive lichen planus</gtr:description><gtr:id>A7ABE879-1BE1-4F43-A7CB-644EF3374097</gtr:id><gtr:impact>Grant applications submitted to NIHR and RfPB. Lead researcher has successfully won an NIHR fellowship during this time to contribute further to the research.</gtr:impact><gtr:outcomeId>56d6b95695bae4.00276972-1</gtr:outcomeId><gtr:partnerContribution>Treatment of patients, design and discussion and leadership of research.</gtr:partnerContribution><gtr:piContribution>Group keen to develop a methodologically efficient design to assess new treatments for women with vulval erosive lichen planus, a rare but debilitating condition. We have worked to help develop study designs, including updates to the multi-arm multi-stage approach, which will be covered in a PhD (Dan B). Eventually calculated that a multi-stage approach could not be used with the particular outcome measures required for the condition. Funding was successfully obtained for the trial which will be run from Nottingham CTU. MRC CTU's Scientific Strategy Group chose not to proceed with this. The unit has developed the first draft of the Statistical Analysis Plan and will engage in an advisory capacity. One member of the unit will serve on the IDMC.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Clinical trials in small populations: methodological challenges and solutions (N68)</gtr:description><gtr:id>A2809EA8-AAB2-4F28-B046-5931FB3EB417</gtr:id><gtr:impact>A two-day meeting bringing together methodologists, applied statisticians, patient representatives and regulators to disseminate state-of-the-art methods and set priorities for methodological research in trials in small populations</gtr:impact><gtr:outcomeId>56d852b956d7b0.68442836-3</gtr:outcomeId><gtr:partnerContribution>Co-applicants and part of the organising committee for a national 2-day workshop</gtr:partnerContribution><gtr:piContribution>Co-applicants and part of the organising committee for a national 2-day workshop</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Warwick</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Clinical trials in small populations: methodological challenges and solutions (N68)</gtr:description><gtr:id>284BD1AB-7D10-47C5-B531-ED21A26ACD07</gtr:id><gtr:impact>A two-day meeting bringing together methodologists, applied statisticians, patient representatives and regulators to disseminate state-of-the-art methods and set priorities for methodological research in trials in small populations</gtr:impact><gtr:outcomeId>56d852b956d7b0.68442836-4</gtr:outcomeId><gtr:partnerContribution>Co-applicants and part of the organising committee for a national 2-day workshop</gtr:partnerContribution><gtr:piContribution>Co-applicants and part of the organising committee for a national 2-day workshop</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Trials Unit</gtr:department><gtr:description>B1- Big Idea- Adaptive Design Outreach officer</gtr:description><gtr:id>AAC96AC3-9E63-4533-A1CD-D1662956312A</gtr:id><gtr:impact>ongoing</gtr:impact><gtr:outcomeId>545a28e1a83d10.57759263-3</gtr:outcomeId><gtr:partnerContribution>This proposal is for an &amp;quot;Adaptive Design Outreach Officer&amp;quot; who would be associated with the Adaptive Designs Working Group (ADWG). The key aim would be to raise awareness and use of adaptive designs across a broad range of diseases and across the development and assessment spectrum. Adaptive methods in this context are defined in its broadest sense end will include Bayesian adaptive dose-finding and group-sequential methods, multi-arm trials, lack-of-benefit stopping rules and sample size reassessment methods. The main activity of the outreach officer would be to proactively engage with applied health researchers to discuss the merits and relative drawbacks of the currently available adaptive designs. In particular, the outreach officer would: 
1. Develop training material on current adaptive designs 
2. Visit each of the UKCRC registered Clinical Trials Units1 to present about the potential of adaptive designs 
3. Facilitate the uptake and implementation of adaptive designs 
4. Support the writing of tutorial papers on adaptive designs</gtr:partnerContribution><gtr:piContribution>Network funding provided for this post</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Biostatistics Unit</gtr:department><gtr:description>B1- Big Idea- Adaptive Design Outreach officer</gtr:description><gtr:id>21135695-66BF-4692-974A-8E2CC00E811F</gtr:id><gtr:impact>ongoing</gtr:impact><gtr:outcomeId>545a28e1a83d10.57759263-2</gtr:outcomeId><gtr:partnerContribution>This proposal is for an &amp;quot;Adaptive Design Outreach Officer&amp;quot; who would be associated with the Adaptive Designs Working Group (ADWG). The key aim would be to raise awareness and use of adaptive designs across a broad range of diseases and across the development and assessment spectrum. Adaptive methods in this context are defined in its broadest sense end will include Bayesian adaptive dose-finding and group-sequential methods, multi-arm trials, lack-of-benefit stopping rules and sample size reassessment methods. The main activity of the outreach officer would be to proactively engage with applied health researchers to discuss the merits and relative drawbacks of the currently available adaptive designs. In particular, the outreach officer would: 
1. Develop training material on current adaptive designs 
2. Visit each of the UKCRC registered Clinical Trials Units1 to present about the potential of adaptive designs 
3. Facilitate the uptake and implementation of adaptive designs 
4. Support the writing of tutorial papers on adaptive designs</gtr:partnerContribution><gtr:piContribution>Network funding provided for this post</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Birmingham Women's and Children's NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Novel clinical trial design in a surgical setting (ROSSINI II)</gtr:description><gtr:id>03650002-1380-4E16-8F41-C7CFCAE40D65</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:outcomeId>56d6bb13dfd4b5.95248674-1</gtr:outcomeId><gtr:partnerContribution>Responsible for submitting the funding application and running the clinical trial</gtr:partnerContribution><gtr:piContribution>Key role in the trial design and sample size calculation. Developed a proposal for the design of the trial, using novel multi-arm multi-stage design, with binary outcome (total: eight arms).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Monash University</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Re-randomisation of patients to a clinical trial</gtr:description><gtr:id>1956F9FA-C1C8-439C-8058-DD728A564950</gtr:id><gtr:impact>Several invited seminars (Leeds, Leicester, LSHTM), conference papers, one published paper.</gtr:impact><gtr:outcomeId>56d6b9eedfabb7.17819060-2</gtr:outcomeId><gtr:partnerContribution>Intellectual input to original design and resulting paper; currently working on follow up projects to demonstrate strengths and weaknesses and to understand practicalities of the design.</gtr:partnerContribution><gtr:piContribution>Intellectual input to original design and resulting paper; currently working on follow up projects to demonstrate strengths and weaknesses and to understand practicalities of the design</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lancaster University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Clinical trials in small populations: methodological challenges and solutions (N68)</gtr:description><gtr:id>CCBD391F-B71C-45CF-81E3-ADBDC8FB8282</gtr:id><gtr:impact>A two-day meeting bringing together methodologists, applied statisticians, patient representatives and regulators to disseminate state-of-the-art methods and set priorities for methodological research in trials in small populations</gtr:impact><gtr:outcomeId>56d852b956d7b0.68442836-1</gtr:outcomeId><gtr:partnerContribution>Co-applicants and part of the organising committee for a national 2-day workshop</gtr:partnerContribution><gtr:piContribution>Co-applicants and part of the organising committee for a national 2-day workshop</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>136000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC HTMR Network award- Adaptive Design Outreach officer</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>407C9B2D-A2FC-4432-88F8-5AD53FDE496D</gtr:id><gtr:outcomeId>56d6b48c74fe60.62718332</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>Performs a combined test for a generalized treatment effect in clinical trials with a time-to-event outcome</gtr:description><gtr:id>347233B3-EDA4-49B0-92DC-F4A0313F5F67</gtr:id><gtr:impact>None yet - just released</gtr:impact><gtr:outcomeId>58b56c25737695.35539594</gtr:outcomeId><gtr:title>A combined test for a generalized treatment effect in clinical trials with a time-to-event outcome</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2017</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FCB880A5-0107-4F8F-8BCD-18EBA200ECC0</gtr:id><gtr:title>Blinded Outcome Assessment Was Infrequently Used and Poorly Reported in Open Trials.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>588641feb5d677.47221415</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CD1C480-7CB9-44C2-A880-92E62FFF022C</gtr:id><gtr:title>Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/541a4254e1d3febac0196c37bb2533c3"><gtr:id>541a4254e1d3febac0196c37bb2533c3</gtr:id><gtr:otherNames>Parmar MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>5a31d7ab9fe281.36443912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>407C657C-6B6F-4A44-B0D7-CF822C1F20A2</gtr:id><gtr:title>A menu-driven facility for sample-size calculation in multiarm, multistage randomized controlled trials with time-to-event outcomes: Update</gtr:title><gtr:parentPublicationTitle>STATA JOURNAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5cb7c3f6f4f4b1062f1b9784e9dd4ae"><gtr:id>f5cb7c3f6f4f4b1062f1b9784e9dd4ae</gtr:id><gtr:otherNames>Bratton Daniel J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1536-867X</gtr:issn><gtr:outcomeId>56d6da4f4d6094.63089535</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12FEA54B-8058-4765-823F-1A466599C568</gtr:id><gtr:title>How do you design randomised trials for smaller populations? A framework.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/541a4254e1d3febac0196c37bb2533c3"><gtr:id>541a4254e1d3febac0196c37bb2533c3</gtr:id><gtr:otherNames>Parmar MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>588641ff23f329.65032736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16902107-5F5D-4911-BB50-FF101BED600B</gtr:id><gtr:title>Stepped wedge randomised controlled trials: systematic review of studies published between 2010 and 2014.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8b76b1b7a1aa911fc1266c31c006562"><gtr:id>c8b76b1b7a1aa911fc1266c31c006562</gtr:id><gtr:otherNames>Beard E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56d6dbf661b718.29772191</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E697977-DC4C-464D-A246-11021EBC93DF</gtr:id><gtr:title>The optimal design of stepped wedge trials with equal allocation to sequences and a comparison to other trial designs.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72ad75d23b5a2ca505a5f53603dcb4d5"><gtr:id>72ad75d23b5a2ca505a5f53603dcb4d5</gtr:id><gtr:otherNames>Thompson JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>5a9421281c13e6.69410199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE0509B7-63B3-465C-A3F6-ED4ACFB9CB40</gtr:id><gtr:title>Comments on 'A modest proposal for dropping poor arms in clinical trials' by Proschan and Dodd.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3088bd154652a88684085b596cb8ca47"><gtr:id>3088bd154652a88684085b596cb8ca47</gtr:id><gtr:otherNames>Bratton DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>56d6dc5c20e1f9.26779488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9805A42-CE25-45B0-9674-9F227F040087</gtr:id><gtr:title>Sample size calculation for a stepped wedge trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a31c72bc30afaaa04f932397f2586d7"><gtr:id>5a31c72bc30afaaa04f932397f2586d7</gtr:id><gtr:otherNames>Baio G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56d6db497fed25.34443189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5ED6262-E454-4A95-83E2-36A02DE2FD52</gtr:id><gtr:title>Adaptive clinical trials in tuberculosis: applications, challenges and solutions.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd0bd9d624f992d94fa7c0f219fb2903"><gtr:id>fd0bd9d624f992d94fa7c0f219fb2903</gtr:id><gtr:otherNames>Davies GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>56d6dc24b36876.97008726</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0ECA4E0-EC7E-4FFE-8CD1-D1040BA12ABB</gtr:id><gtr:title>Analysis and reporting of stepped wedge randomised controlled trials: synthesis and critical appraisal of published studies, 2010 to 2014.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8772bdefc0171096ff17c4c62ec90aca"><gtr:id>8772bdefc0171096ff17c4c62ec90aca</gtr:id><gtr:otherNames>Davey C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56d6dbbf9c6e81.19963036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>885DF6C7-0E88-4B96-9482-1362A784F090</gtr:id><gtr:title>Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3088bd154652a88684085b596cb8ca47"><gtr:id>3088bd154652a88684085b596cb8ca47</gtr:id><gtr:otherNames>Bratton DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>587de3279cc006.68735342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D145C3A2-F479-451A-891B-2E55F10F8108</gtr:id><gtr:title>Risk of selection bias in randomised trials.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58864159a2f774.70601050</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A089946-F092-47DB-BD77-85A6A9376D87</gtr:id><gtr:title>Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b3c006984ba4b34748adc08e2419130"><gtr:id>0b3c006984ba4b34748adc08e2419130</gtr:id><gtr:otherNames>Bogaerts J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>56d6d9d52e6a04.30331796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D70B5698-6E85-49D0-8C12-15702072B81A</gtr:id><gtr:title>A re-randomisation design for clinical trials.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>56d6dcbe544ce1.79938491</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9ACE241-F5A3-4FCA-8F21-6E2509686B3E</gtr:id><gtr:title>DOOR/RADAR: A Gateway Into the Unknown?</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea73e5c0a9951b8511cd9c8aec3c510"><gtr:id>2ea73e5c0a9951b8511cd9c8aec3c510</gtr:id><gtr:otherNames>Phillips PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56cdb74ee05155.83106697</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E886C55-F450-4565-A035-5CCF3C93FAFE</gtr:id><gtr:title>Reporting and methodological quality of sample size calculations in cluster randomized trials could be improved: a review.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51f42791ca36d6e8dbd2ec90c0be9565"><gtr:id>51f42791ca36d6e8dbd2ec90c0be9565</gtr:id><gtr:otherNames>Rutterford C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>56d6da7fcc1610.47503350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23553247-18CD-48B0-A86A-73DCF499C0E6</gtr:id><gtr:title>Designing a stepped wedge trial: three main designs, carry-over effects and randomisation approaches.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1af5840e7bd12264ce3141ce9d41bd11"><gtr:id>1af5840e7bd12264ce3141ce9d41bd11</gtr:id><gtr:otherNames>Copas AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56d6db1611ccc6.70772841</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D322BF35-F4E8-4867-A225-68578B530A72</gtr:id><gtr:title>Adaptive designs in clinical trials: why use them, and how to run and report them.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b4ce11d600cea298d5911acf3126187"><gtr:id>7b4ce11d600cea298d5911acf3126187</gtr:id><gtr:otherNames>Pallmann P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>5a992a89a076a5.84794176</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12960EFD-E30A-4A0C-B339-CC74EB30D379</gtr:id><gtr:title>How important is randomisation in a stepped wedge trial?</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83c90920ebb2c122fb1355f3d53131cb"><gtr:id>83c90920ebb2c122fb1355f3d53131cb</gtr:id><gtr:otherNames>Hargreaves JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56d6dae5722c95.19154561</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FD94E65-25A8-472B-A375-8052BADE7BBC</gtr:id><gtr:title>Five questions to consider before conducting a stepped wedge trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83c90920ebb2c122fb1355f3d53131cb"><gtr:id>83c90920ebb2c122fb1355f3d53131cb</gtr:id><gtr:otherNames>Hargreaves JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56d6db87c25571.85920311</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18B79D11-41DF-4316-A58A-08CC2FA81BB6</gtr:id><gtr:title>Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d52cfc0ce641dd5899c5482937339da6"><gtr:id>d52cfc0ce641dd5899c5482937339da6</gtr:id><gtr:otherNames>Royston P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>58b6a9ef7aabd0.37539321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F1CC25A-F389-4814-8391-05FAF45CA25E</gtr:id><gtr:title>Internet-accessed sexually transmitted infection (e-STI) testing and results service: A randomised, single-blind, controlled trial.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f27fc302d43bdeff6610b3a7bed74ce8"><gtr:id>f27fc302d43bdeff6610b3a7bed74ce8</gtr:id><gtr:otherNames>Wilson E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>5a679019e8baa7.96702136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43CFB389-89E1-4F78-A5BF-534B62E88444</gtr:id><gtr:title>Methods for sample size determination in cluster randomized trials.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51f42791ca36d6e8dbd2ec90c0be9565"><gtr:id>51f42791ca36d6e8dbd2ec90c0be9565</gtr:id><gtr:otherNames>Rutterford C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>56d6daaad2e429.53442816</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12023/29</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>FB395309-E202-4FE8-87B0-041A3D72D4D4</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.5  Research design and methodologies (aetiology)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>